Clinical Trial Update: TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for TIGER-1 evaluating rociletinib (CO-1686) vs erlotinib in EGFR-mutant metastatic non-small cell lung cancer; the study is terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• rociletinib (rociletinib)

Snippet

Sponsor: Clovis Oncology, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2019-04-30